Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted 04 November, 2009 and appeared in  Issue 494Cardiovascular HealthCulturally Aware CareMedicationType 2 Diabetes

Statins May Increase Diabetes Risk

Cholesterol-lowering statin drugs do not reduce the risk of diabetes and might modestly elevate the chances of developing the condition, researchers found in a pooled analysis of trial data.

Advertisement

Lead investigator Dr. Swapnil Rajpathak stated that, "Contrary to our expectation, we did not find any benefit of statins on diabetes risk. In fact, there is a suggestion that statins may be associated with increased risk -- which needs to be explored further."

The role of statins in lowering high cholesterol and protecting the heart is well established, but their relationship with diabetes is controversial, Rajpathak, Albert Einstein College of Medicine, New York, and colleagues note in the journal Diabetes Care. One Scottish trial reported a small protective effect of statins on diabetes.

To investigate further, the researchers pooled data from this trial and five other randomized placebo-controlled trials of statins involving a total of more than 57,000 adults.

After an average follow-up of 3.9 years, 2,082 participants developed diabetes. When data from the Scottish trial were excluded, there appeared to be a small but significant 13 percent increased relative risk of diabetes developing in those who received statin therapy. When the Scottish trial was included in the analysis, the risk of diabetes with statin therapy was attenuated (6 percent increased risk).

However, the researchers emphasize that there were a number of possible factors that may have influenced the results. In addition, Rajpathak stressed that the benefits of statins on heart disease "by far outweigh any detrimental effects on ... diabetes risk."

In an accompanying editorial, Dr. Christie M. Ballantyne of Baylor College of Medicine, Houston, Texas, and colleagues agree, pointing out that if future studies confirm such a connection, "Because cardiovascular disease accounts for almost two-thirds of deaths in people with diabetes, the protective effect of statins on this major complication may suffice to support their use despite a potential risk of new-onset diabetes."

Diabetes Care, October 2009.

 

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 04 November, 2009 and appeared in  Issue 494Cardiovascular HealthCulturally Aware CareMedicationType 2 Diabetes

Past five issues: Diabetes Clinical Mastery Series Issue 85 | Issue 626 | Special Edition - Getting Patients on Track | Diabetes Clinical Mastery Series Issue 84 | Issue 625 |

2012 Most Popular Articles:

ADA/EASD Issue New Hyperglycemia Management Guidelines
Posted April 26, 2012
Type 2 More Dangerous in Children
Posted May 03, 2012
It’s the Variety of Fruit-and-Veggie That Lower Diabetes Risk
Posted May 03, 2012
Questioning Carbohydrate Restriction in Diabetes Management
Posted May 18, 2012
Ultra-Long-Acting Insulin Degludec, Two New Studies
Posted April 26, 2012
Eating Low Glycemic Index Foods at Breakfast Can Control Blood Sugar throughout the Day
Posted April 18, 2012
Metformin May Treat a Leading Cause of Blindness
Posted May 10, 2012
A Candy Treatment that Fights Diabetes and May Replace TZD's?
Posted May 10, 2012
Metformin May Not Be the Golden Pill After All for Treating Type 2 Diabetes
Posted April 18, 2012
Doubts Over Long Term Effectiveness of Group Education for Diabetes Patients
Posted May 03, 2012

See more most popular…


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Bernstein | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Marilyn Porter, RD, CDE | Melissa Diane Smith | Paul Chous, M.A., OD | Philip A. Wood PhD | Sheri R. Colberg PhD | Sherri Shafer | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |
 
Diabetes In Control Advertisers
 
 
Cast Your Vote
Now that once-weekly GLP-1 is available, which product are you recommending for your type 2 patients?

Navigate Diabetes In Control
Announcement:



Search Articles On Diabetes In Control